Company intelligence / Profile preview
Biosyngen
Singapore, Singaporebiosyngen.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
Leading pipeline product BRG01 is in pivotal Phase II clinical trials. BST02 and BRL03 are in Phase I trials with completion anticipated in 2025. BRG01 has received Orphan Drug Designation from the FDA.
- Therapeutic areas
- Oncology
- Modalities
- CAR-TTCR-TTILMulti-specific antibodiesCell Therapy
- Industry
- Biotech
02
Drug pipeline
15 assets14 more assets in the full pipeline.
03
Partnerships
Sun Yat-sen University Cancer CenterGuangzhou District Government
Beyond the preview
Go deeper on Biosyngen.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Biosyngen.